Advances in anlotinib combined with cranial radiotherapy for brain metastases from advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) has a persistently high incidence and mortality rate, and brain metastasis is one of the common complications with a poor prognosis. At present, cranial radiotherapy is a key treatment for controlling the progression of brain metastases, but its efficacy remains limited. Anlotinib is a multitarget tyrosine kinase inhibitor that can significantly prolong the survival of patients with advanced NSCLC. Clinical studies have found that anlotinib combined with cranial radiotherapy can delay the progression of brain metastases with good safety. This review mainly discusses the mechanisms and clinical efficacy of this combination strategy in NSCLC with brain metastases, aiming to provide a new and effective therapeutic option for these patients.

Authors

Institutions

Publication Details

Journal
Frontiers in Neurology
Published
2026-11-19
DOI
https://doi.org/10.3389/fneur.2026.2004058
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advances in anlotinib combined with cranial radiotherapy for brain metastases from advanced non-small cell lung cancer

龙凤尧, Yaqian Li, Nuoyu Yan, Lan Sun
Frontiers in Neurology
Brain Metastases and Treatment
article

Advances in anlotinib combined with cranial radiotherapy for brain metastases from advanced non-small cell lung cancer

龙凤尧, Yaqian Li, Nuoyu Yan, Lan Sun
article en

Abstract

Non-small cell lung cancer (NSCLC) has a persistently high incidence and mortality rate, and brain metastasis is one of the common complications with a poor prognosis. At present, cranial radiotherapy is a key treatment for controlling the progression of brain metastases, but its efficacy remains limited. Anlotinib is a multitarget tyrosine kinase inhibitor that can significantly prolong the survival of patients with advanced NSCLC. Clinical studies have found that anlotinib combined with cranial radiotherapy can delay the progression of brain metastases with good safety. This review mainly discusses the mechanisms and clinical efficacy of this combination strategy in NSCLC with brain metastases, aiming to provide a new and effective therapeutic option for these patients.

Frontiers in NeurologyVol. 17
Chongqing Medical University (CN)
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon